Yes, Ozempic is a GLP-1 receptor agonist. Its active ingredient, semaglutide, is a lab-modified version of GLP-1 (glucagon-like peptide-1), a hormone your body naturally produces after eating. The key difference between the drug and the natural hormone is staying power: your body’s own GLP-1 breaks down in about two minutes, while semaglutide has been engineered to last long enough for a once-weekly injection.
What GLP-1 Does in Your Body
Every time you eat, cells in your gut release GLP-1. This hormone triggers a chain of events designed to manage the surge of incoming sugar. It signals your pancreas to release more insulin, which pulls sugar out of your bloodstream and into cells. At the same time, it tells another part of the pancreas to stop releasing glucagon, a hormone that would otherwise prompt your liver to dump even more sugar into your blood. The net effect is tighter blood sugar control right when you need it most.
GLP-1 also acts on the stomach and brain. It slows the rate at which food leaves your stomach, which spreads out the sugar spike from a meal and creates a lingering feeling of fullness. In the brain, it dials down appetite signals. These combined effects explain why drugs that mimic GLP-1 help with both blood sugar management and weight loss.
How Semaglutide Improves on the Natural Hormone
Natural GLP-1 is broken down by an enzyme called DPP-4 almost immediately after release, giving it a half-life of roughly two minutes. That’s far too short to be useful as a medication. Semaglutide is structurally modified so that it resists this enzyme, binds to a protein in the blood for slow release, and activates the same GLP-1 receptors throughout the body. The result is a drug that works through the exact same biological pathways as your own GLP-1 but stays active for about a week.
What Ozempic Is Approved to Treat
The FDA has approved Ozempic specifically for adults with type 2 diabetes. It serves three purposes in that population: improving blood sugar control alongside diet and exercise, reducing the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) in those with established heart disease, and protecting kidney function in those with chronic kidney disease.
In real-world use, patients starting on the 1.0 mg weekly dose see an average HbA1c reduction of 1.2%, and those who stay on it consistently average a 1.4% drop. For context, HbA1c reflects your average blood sugar over about three months, and a reduction of that size is clinically meaningful for diabetes management.
Ozempic is not FDA-approved for weight loss, even though weight loss is a well-known side effect. That approval belongs to Wegovy, which contains the same semaglutide molecule but at a higher maximum dose (2.4 mg weekly compared to Ozempic’s 2 mg cap).
Ozempic vs. Wegovy
Because both drugs use semaglutide, people often confuse them. The distinction comes down to dose and indication. Ozempic is a diabetes drug with cardiovascular and kidney benefits. Wegovy is approved for weight management in adults and children 12 and older, for a type of liver disease called MASH, and for cardiovascular risk reduction in people with obesity and heart disease, regardless of whether they have diabetes.
Wegovy’s higher ceiling dose matters for weight loss outcomes. Research suggests the additional semaglutide at 2.4 mg provides greater appetite suppression and more significant weight reduction than Ozempic’s maximum dose.
How the Dosing Works
Ozempic follows a gradual ramp-up schedule. You start at 0.25 mg once weekly for four weeks. This starting dose isn’t meant to control blood sugar on its own; it’s purely to let your body adjust. After four weeks, you move to 0.5 mg weekly. If blood sugar control still isn’t where it needs to be after at least another four weeks, your dose can increase to 1 mg weekly. The entire titration process takes a minimum of eight weeks before reaching a full therapeutic dose.
Cardiovascular and Kidney Benefits
Beyond blood sugar, Ozempic has proven cardiovascular benefits. In the large SELECT trial, semaglutide reduced major adverse cardiovascular events by 20% among participants with obesity and established heart disease. The FDA also approved Ozempic to slow kidney decline in adults with type 2 diabetes and chronic kidney disease, making it one of the few diabetes drugs with formal approvals across blood sugar, heart, and kidney outcomes.
Common Side Effects
Most side effects are gut-related, which makes sense given that GLP-1 receptors line the digestive tract. Nausea is the most frequent, affecting 15% to 20% of users. Vomiting occurs in 5% to 9%, diarrhea in about 8%, abdominal pain in 6% to 7%, and constipation in 3% to 7%. These symptoms tend to be worst early in treatment, particularly around dose increases.
The delayed gastric emptying that causes fullness can also cause discomfort. This effect is strongest after the first dose and gradually diminishes with continued use, a phenomenon called tachyphylaxis. Some evidence suggests gastric emptying can remain impaired for up to eight weeks, which is worth knowing if you’re scheduled for any procedure requiring an empty stomach.
GLP-1 Drugs Beyond Ozempic
Ozempic is one of several GLP-1 receptor agonists on the market. Others include liraglutide (sold as Victoza for diabetes and Saxenda for weight loss), dulaglutide (Trulicity), and tirzepatide (Mounjaro and Zepbound), which targets both GLP-1 and another gut hormone receptor called GIP. Each varies in dosing frequency, approved uses, and potency, but they all work by leveraging the same core GLP-1 pathway that your body uses naturally after every meal.